ONC - BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit

2025-05-08 09:24:42 ET

Summary

• BeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra.
• Brukinsa, a BTK inhibitor, has shown impressive revenue growth and market share gains, with significant potential for future expansion and revenue generation.
• Tevimbra, while facing intense competition, shows promise with recent FDA approvals and ongoing trials targeting various cancers.
• ONC's robust pipeline, strategic partnerships, and strong financial position it well for sustained growth, but current valuation suggests cautious investment at prices above $200.

Company Background

BeiGene, Ltd. ( ONC ), according to its latest 10-Q report , describes itself as a

a leading global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide.

It develops and commercializes innovative drugs for the treatment of cancer, particularly chronic lymphocytic leukemia ((CLL)), which has a global diagnosis rate of approximately 191,000 each year , of which approximately 23,000 are in the U.S. alone . The company was founded in 2010 (as BeiGene) by John Oyler, an American entrepreneur, who continues to serve as its CEO, and Xiaodong Wang, a Chinese biochemist, who continues to serve as Chairman of its Scientific Advisory Board....

For further details see: